6,168 people from the geriatric population aged 65 and over...
"Abstract
Older age (>60 years) has been identified as the main risk factor for COVID-19. In this study, we aimed to evaluate the efficacy of Pfizer-BioNTech and CoronaVac vaccines against COVID-19 infection, serious illness, and mortality in the geriatric population. We found that 2 doses of CoronaVac vaccine were ineffective in protecting against COVID-19 infection in people over 65 years of age, while the vaccine efficacy (VE) of the mRNA vaccine against COVID-19 was 80%. The VE of full vaccination with BioNTech was 89% against hospitalization, 79% against death, and 79% against intensive care unit (ICU) admission.
However, the VE of full vaccination with CoronaVac was 50% against hospitalization, 53% against ICU admission, and 56% against death. In conclusion, we found that the mRNA vaccine has higher efficacy against severe COVID-19 infection and mortality in the geriatric population than the inactivated vaccine. Booster doses of vaccines should be considered in increasing the effectiveness of inactivated vaccines. Given the potential of SARS-CoV-2 mutations evading vaccination protection and the risk of reduced immunity over time, regular monitoring of vaccine effectiveness in the real world is critical."
Short Communication
Published: 09 May 2023
Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population
Yasemin Gen? Bah?e, ?mer Acer & Osman ?z?do?ru
Current Microbiology volume 80, Article number: 206 (2023)
link.springer.com/article/10.1007/s00284-023-03322-z